ARCT-810

DB17683InvestigationalGene Therapies

ARCT-810 is an mRNA replacement therapy that delivers ornithine transcarbamylase mRNA to hepatocytes.

Code names
ARCT-810

What you can answer from here — as of April 23, 2025

3Clinical trialsPhase, status and sponsor resolved per trial
Sign in

Which companies are running trials of ARCT-810, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In